Novartis AG

Sanofi and Orano Med's AlphaMedix (212Pb-dotamtate) achieved all primary efficacy endpoints in a Phase 2 study for gastroenteropancreatic neuroendocrine tumors, showing clinically meaningful overall response rates.

Amgen's Phase III VESALIUS-CV trial met both primary endpoints, demonstrating that Repatha significantly reduces major adverse cardiovascular events in high-risk patients without prior heart attack or stroke.

The FDA has approved remibrutinib (Rhapsido) as the first oral Bruton's tyrosine kinase inhibitor for treating chronic spontaneous urticaria in adults who remain symptomatic despite antihistamine therapy.

Cue Biopharma has appointed Dr. Usman Azam as President and CEO, effective September 29, 2025, bringing over 25 years of drug development experience including CAR-T cell therapy leadership at Novartis.

Novartis will launch a direct-to-patient platform on November 1, 2025, offering Cosentyx at a 55% discount off list price to cash-paying patients in the US.

Moonlake Immunotherapeutics' experimental drug sonelokimab delivered mixed results in two late-stage hidradenitis suppurativa trials, with one study meeting statistical significance but falling short of investor expectations.

MannKind Corporation has appointed Dr. Ajay Ahuja as Chief Medical Officer, bringing over two decades of biopharmaceutical leadership experience to advance the company's inhaled therapeutics pipeline.

Amneal Pharmaceuticals has submitted a Biologics License Application to the FDA for a biosimilar to XOLAIR (omalizumab), developed in partnership with Kashiv BioSciences.

Tiziana Life Sciences announces advancement of TZLS-501, a fully human anti-IL-6 receptor monoclonal antibody targeting both membrane-bound and soluble forms of IL-6R with dual mechanism of action.

Over 20 pharmaceutical and biotech companies are actively developing more than 20 therapeutic candidates for Huntington's disease at various clinical and preclinical stages.